PA5-42007

antibody from Invitrogen Antibodies

Targeting: PRPS2

Western blot

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: PA5-42007 - Provider product page
Provider: Invitrogen Antibodies
Product name: PRPS2 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Peptide sequence: VSPDAGGAKR VTSIADRLNV EFALIHKERK KANEVDRMVL VGDVKDRVAI Sequence homology: Cow: 100%; Dog: 100%; Guinea Pig: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Rabbit: 100%; Rat: 100%; Zebrafish: 100%
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.5 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

PRPS2 protein structure - PA5-42007 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 PRPS2 depletion and apoptosis of spermatogenic cells. ( a ) qRT-PCR and Western blot analysis confirmed that PRPS2 was successfully downregulated by gene silencing and upregulated by PRPRS2 overexpression in both GC1 and GC2 cells. ( b ) Flow cytometry analysis shows that PRPS2 depletion promotes the apoptosis of GC1 cells. ( c ) Flow cytometry analysis shows that PRPS2 depletion promotes the apoptosis of GC2 cells (abscissa: cell count; ordinate: the fluorescence intensity). ( d ) Western blot analysis indicates that PRPS2 depletion activates the expression of apoptotic proteins (values beneath blots are relative to the control). *Significantly different compared with negative control, P < 0.05 by independent-samples t -test. shPRPS2: small-hairpin RNA gene silencer; NC: negative control; PRPS2: overexpression; PRPS2: phosphoribosyl-pyrophosphate synthetase 2; qRT-PCR: quantitative real-time polymerase chain reaction; APC-A: Allophycocyanin-A.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Correlation of PRPS2 expression with hypospermatogenesis. ( a ) H and E staining of the testis with normal spermatogenesis. ( b ) H and E staining of normal cauda epididymidis. ( c ) H and E staining of a testis with hypospermatogenesis. ( d ) H and E staining of cauda epididymidis in hypospermatogenesis. ( e ) PRPS2 expression was detected in normal testis by IHC. ( f ) PRPS2 expression was detected in a testis with hypospermatogenesis by IHC. Scale bars = 50 mum. ( g ) PRPS2 expression was detected in testis with normal spermatogenesis and hypospermatogenesis by Western blot. ( h ) PRPS2 expression was detected in testis tissues with normal spermatogenesis and hypospermatogenesis by qRT-PCR. *Hypospermatogenesis group compared with normal control, P < 0.05 by independent-samples t -test. Red arrow: spermatogonia; Black arrow: spermatocyte. PRPS2: phosphoribosyl-pyrophosphate synthetase 2; H and E: hematoxylinand and eosin; IHC: immunohistochemical; qRT-PCR: quantitative real-time polymerase chain reaction.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 PRPS2 targetes E2F1 and activation of the P53/Bcl-xl/Bcl-2 signal pathway. ( a ) Colocation of PRPS2 and E2F1 in GC1 and GC2 cells and normal testis tissue was observed by double immunofluorescent staining. ( b ) After transfection, the expression levels of PRPS2 and E2F1 were detected by double immunofluorescent staining. ( c ) Western blot was used to measure the expression levels of the E2F1/P53/Bcl-xl/Bcl-2 signaling pathway. Values beneath the blots are relative to the control. White arrow: colocation. PRPS2: phosphoribosyl-pyrophosphate synthetase 2; NC: negative control; E2F1: E2F transcription factor 1.